DexCom, Inc. DXCM reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus ...

Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

SAN DIEGO - Dexcom reported revenue growth of 15% year-over-year to $1.157 billion for the second quarter of 2025.

The recall affects Dexcom G6, G7, ONE, and ONE+ continuous glucose monitor receivers but not the smartphone apps or insulin ...

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 15.2% year on ...

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and identified concerns in manufacturing processes and quality management.

FDA recalls Dexcom glucose monitors (G6, G7, ONE models) due to alert issues posing severe health risks. Read more here.

With an overall MARD of 8.0%, 3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range. 4-8 ...

FDA clears Dexcom G7 15-Day CGM for adults, offering 15.5 days of wear and a MARD of 8.0% for improved diabetes management. New features include Apple Watch connectivity, medication logging, and ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections of the company’s facilities in San Diego ...

DexCom, Inc. (DXCM - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the ...